Greenland Mines Ltd
Company Profile
Business description
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.
Contact
1300 South Boulevard
Unit D
CharlotteNC28203
USAT: +1 833 931-6330
Sector
Basic Materials
Stock type
Cyclical
Industry
Other Precious Metals & Mining
Fiscal Year End
Employees
5
Stocks News & Analysis
stocks
Why stocks sometimes fall for no obvious reason
stocks
Poor organic growth obscured by acquisition for ASX listed share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,882.60 | 20.50 | -0.23% |
| CAC 40 | 8,258.26 | 142.51 | 1.76% |
| DAX 40 | 25,389.10 | 500.54 | 2.01% |
| Dow JONES (US) | 50,579.70 | 294.04 | 0.58% |
| FTSE 100 | 10,466.26 | 22.79 | 0.22% |
| HKSE | 25,674.90 | 68.87 | 0.27% |
| NASDAQ | 26,343.97 | 50.87 | 0.19% |
| Nikkei 225 | 64,996.09 | 162.10 | -0.25% |
| NZX 50 Index | 13,069.74 | 99.46 | 0.77% |
| S&P 500 | 7,473.47 | 27.75 | 0.37% |
| S&P/ASX 200 | 8,657.80 | 18.80 | -0.22% |
| SSE Composite Index | 4,148.23 | 4.34 | -0.10% |